ARK Investment Management LLC Buys 1,363 Shares of Cellebrite DI Ltd. $CLBT

ARK Investment Management LLC raised its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 1.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 86,063 shares of the company’s stock after acquiring an additional 1,363 shares during the period. ARK Investment Management LLC’s holdings in Cellebrite DI were worth $1,377,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Assetmark Inc. bought a new stake in shares of Cellebrite DI in the 1st quarter worth approximately $33,000. Signaturefd LLC lifted its holdings in shares of Cellebrite DI by 68.3% during the second quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock valued at $32,000 after purchasing an additional 819 shares in the last quarter. Catalyst Capital Advisors LLC purchased a new stake in Cellebrite DI in the first quarter worth about $51,000. Virtus Advisers LLC bought a new stake in shares of Cellebrite DI in the 1st quarter valued at approximately $63,000. Finally, Hennessy Advisors Inc. purchased a new stake in shares of Cellebrite DI in the second quarter worth approximately $83,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CLBT. Wall Street Zen upgraded Cellebrite DI from a “hold” rating to a “buy” rating in a report on Friday, September 26th. Needham & Company LLC decreased their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, August 14th. Lake Street Capital cut their price objective on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 15th. Weiss Ratings restated a “sell (d+)” rating on shares of Cellebrite DI in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. raised their price target on Cellebrite DI from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $21.75.

Cellebrite DI Trading Down 3.9%

CLBT stock opened at $17.78 on Thursday. The firm has a 50 day moving average of $17.49 and a 200-day moving average of $16.93. Cellebrite DI Ltd. has a 12-month low of $13.10 and a 12-month high of $26.30. The company has a market cap of $4.26 billion, a price-to-earnings ratio of -23.39, a PEG ratio of 3.36 and a beta of 1.29.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.01. The firm had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.